「dos」の検索結果

Recommends hydrocortisone replacement dosing of 15–20 mg total daily, administered as a single dose or divided doses with the highest dose given in the morning upon awakening and the second dose in the afternoon (two-dose regimen) or second and third doses at lunch and late afternoon (three-dose regimen). Use when initiating glucocorticoid replacement for adrenal insufficiency; triggers include diagnosing adrenal insufficiency requiring glucocorticoid replacement.

日本語の概要は準備中です。原文の説明を表示しています。

Suggests using hydrocortisone 15–25 mg or cortisone acetate 20–35 mg daily in two or three divided oral doses for adult primary adrenal insufficiency (PAI) patients initiating glucocorticoid replacement. The highest dose is given upon awakening, with the second dose either early afternoon (≈2 h after lunch) or split into lunch and afternoon doses; consider total daily dose calculation based on chosen formulation and frequency.

日本語の概要は準備中です。原文の説明を表示しています。

Determines age- and body weight-appropriate glucocorticoid dosage for pediatric patients with primary aldosteronism, particularly glucocorticoid-remediable aldosteronism (GRA), to avoid over-treatment. Use when prescribing glucocorticoids to children with confirmed or suspected PA; triggers include pediatric PA, GRA, or need to dose glucocorticoid based on age and weight.

日本語の概要は準備中です。原文の説明を表示しています。

Interprets the postural stimulation test to detect angiotensin II‑unresponsive aldosterone‑producing adenoma (APA) or familial hyperaldosteronism type I (FH‑I) when aldosterone fails to rise with upright posture. Triggered by clinical cues such as “postural stimulation test shows no aldosterone increase”, “suspected APA with non‑responsive aldosterone”, or “evaluating FH‑I in young patients with early‑onset hypertension and hypokalemia”.

日本語の概要は準備中です。原文の説明を表示しています。

Tokenizadores rápidos otimizados para pesquisa e produção. Implementação em Rust que tokeniza 1GB em menos de 20 segundos. Suporta algoritmos BPE, WordPiece e Unigram. Treine vocabulários customizados, rastreie alinhamentos, gerencie padding/truncagem. Integração perfeita com transformers. Use quando precisar de tokenização de alto desempenho ou treinamento de tokenizadores customizados.

日本語の概要は準備中です。原文の説明を表示しています。

Framework de dados para construir aplicações LLM com RAG. Especializado em ingestão de documentos (300+ conectores), indexação e consultas. Inclui índices vetoriais, mecanismos de consulta, agentes e suporte multimodal. Use para perguntas sobre documentos, chatbots, recuperação de conhecimento ou construção de pipelines RAG. Ideal para aplicações LLM centradas em dados.

日本語の概要は準備中です。原文の説明を表示しています。

電子カルテに組み込む臨床判断支援を設計し、薬の相互作用や用量の検証、臨床スコアの計算、警告の重要度に応じた画面制御とテストを実装するスキル。

• 薬の相互作用とアレルギー確認の実装
• 患者情報に応じた用量検証
• NEWS2などの臨床スコアの実装

Planificación persistente basada en archivos para tareas multipaso de agentes de IA. Mantiene task_plan.md, findings.md y progress.md en disco; los hooks del ciclo de vida inyectan contexto seleccionado de planificación del proyecto. La recuperación automática solo lee los archivos de planificación del proyecto. session-catchup.py --metadata, solicitado de forma explícita, puede inspeccionar metadatos locales de sesiones del mismo proyecto; --replay puede emitir extractos limitados y enmarcados con nonce. El modo con gate opcional solo puede solicitar que el host continúe si este lo admite y nunca ejecuta comandos declarados en Markdown. El skill no tiene ninguna ruta de carga por red. Úsalo para investigación o trabajo que requiera 5 o más llamadas a herramientas.

日本語の概要は準備中です。原文の説明を表示しています。

Structured intelligence dossiers on companies, people, markets, or domains, with source triangulation and fact/inference discipline. Use when preparing a deal-prep dossier, executive briefing, or due-diligence overview.

日本語の概要は準備中です。原文の説明を表示しています。

Orientação LGPD para operações de tratamento no Brasil. Cobre bases legais (Art. 7º e Art. 11), RIPD, incidentes (Arts. 48-49), direitos dos titulares (Art. 18) e transferências internacionais. Triggers: LGPD, RIPD, ANPD, proteção de dados, dados pessoais, consentimento, encarregado, DPO Brasil, incidente de dados, legítimo interesse.

日本語の概要は準備中です。原文の説明を表示しています。

Expert knowledge for Azure DDoS Protection development including troubleshooting, best practices, decision making, architecture & design patterns, security, configuration, and integrations & coding patterns. Use when enabling DDoS IP/Network Protection, tuning policies, analyzing logs/metrics, or integrating NVAs and Azure Policy, and other Azure DDos Protection related development tasks. Not for Azure Firewall (use azure-firewall), Azure Firewall Manager (use azure-firewall-manager), Azure Web Application Firewall (use azure-web-application-firewall), Azure Virtual Network (use azure-virtual-network).

日本語の概要は準備中です。原文の説明を表示しています。

Turn in vitro potency and animal pharmacokinetics into a defensible human dose projection — the arithmetic that decides whether a compound can reach its target concentration safely. Use this skill for non-compartmental analysis of a concentration-time profile (AUC, Cmax, terminal half-life, clearance, volume of distribution), one- and two-compartment simulation of a dosing regimen, interspecies allometric scaling, human-equivalent dose conversion by body surface area, and the exposure margin between a projected therapeutic concentration and a toxicology no-effect level. Also trigger on non-compartmental analysis, AUC, clearance, volume of distribution, allometric scaling, human equivalent dose, first-in-human, NOAEL, therapeutic index, or exposure margin.

日本語の概要は準備中です。原文の説明を表示しています。

Front-door router voor het werken aan een regelrecht-dossier. Gebruik dit aan het begin van een dossier, of bij twijfel over waar te beginnen — het triageert de situatie en routeert naar de juiste skill (regelrecht-stelselanalyse voor desk-review/corpus-completion, regelrecht-audit-products voor live expert-validatie) en de juiste volgorde. Bevat het routeringsprincipe: feitelijke defecten routeren naar de desk, oordeels-/praktijkvragen naar de workshop. Dossier-agnostisch.

日本語の概要は準備中です。原文の説明を表示しています。

Calculates the lowest effective glucocorticoid dose (dexamethasone or prednisone) to normalize blood pressure and serum potassium in glucocorticoid-remediable aldosteronism (GRA/FH-I) by titrating to biochemical and clinical targets. Indicated when initiating medical treatment for confirmed GRA, triggered by findings such as early-onset hypertension, family history of stroke before age 40, spontaneous hypokalemia, or suppressed plasma renin activity with elevated aldosterone.

日本語の概要は準備中です。原文の説明を表示しています。

Recommends initiating hydrocortisone replacement at a total starting dose of 8 mg/m2 body surface area per day, given in three or four divided doses, for children with confirmed primary adrenal insufficiency (PAI). Use when starting glucocorticoid therapy in pediatric PAI patients, adjusting the dose according to individual clinical response, growth, and need for stress coverage.

日本語の概要は準備中です。原文の説明を表示しています。

Recommends initiating fludrocortisone 50–100 µg daily for mineralocorticoid replacement in adults with confirmed aldosterone deficiency (e.g., low aldosterone, elevated renin) and no salt restriction. Use when aldosterone deficiency is confirmed in a patient with primary adrenal insufficiency (PAI) presenting with salt craving or postural hypotension.

日本語の概要は準備中です。原文の説明を表示しています。

Determines when to avoid aldosterone suppression testing in hypertensive patients with a positive PA screen who have normokalemia and suppressed aldosterone below assay‑specific cutoffs (<11 ng/dL immunoassay or <8 ng/dL LC‑MS/MS), indicating low likelihood of primary aldosteronism. Use when a clinician asks whether to skip confirmatory suppression testing based on low pretest probability.

日本語の概要は準備中です。原文の説明を表示しています。

Guide pre-endoscopy management decisions for patients on GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide etc.), deciding whether to proceed, delay, or modify the approach based on GI symptoms, fasting status, and indication. Trigger when a clinician asks about GLP-1 RA and endoscopy, semaglutide before colonoscopy, Ozempic before procedure, or whether to hold a GLP-1 agonist before endoscopy.

日本語の概要は準備中です。原文の説明を表示しています。

Kit de ferramentas abrangente para desenvolvimento com a biblioteca CocoIndex. Use quando os usuários precisarem criar pipelines de transformação de dados (flows), escrever funções personalizadas ou operar flows via CLI ou API. Abrange a construção de workflows ETL para processamento de dados de IA, incluindo incorporação de documentos em bancos de dados vetoriais, construção de grafos de conhecimento, criação de índices de busca ou processamento de fluxos de dados com atualizações incrementais.

日本語の概要は準備中です。原文の説明を表示しています。

Quando o usuário quer adicionar, corrigir ou otimizar schema markup e dados estruturados no seu site. Use também quando o usuário menciona "schema markup", "dados estruturados", "JSON-LD", "rich snippets", "schema.org", "FAQ schema", "product schema", "review schema" ou "breadcrumb schema". Para problemas de SEO mais amplos, consulte seo-audit.

日本語の概要は準備中です。原文の説明を表示しています。

Processamento escalável de dados para workloads de ML. Execução em streaming em CPU/GPU, suporta Parquet/CSV/JSON/imagens. Integra-se com Ray Train, PyTorch, TensorFlow. Escala de uma única máquina para centenas de nós. Use para inferência em lote, pré-processamento de dados, carregamento de dados multi-modal ou pipelines distribuídos de ETL.

日本語の概要は準備中です。原文の説明を表示しています。

Implementa e valida dados estruturados schema.org em JSON-LD — Organization, Article, FAQPage, Product, BreadcrumbList. Use quando o usuário disser "schema", "dados estruturados", "JSON-LD", "rich snippet", "FAQ schema", "schema.org".

日本語の概要は準備中です。原文の説明を表示しています。

Pharmacokinetic and pharmacodynamic modelling and simulation - non-compartmental analysis, compartmental and population PK, PK/PD and exposure-response, TMDD, PBPK orientation, bioequivalence, allometric scaling and first-in-human dose, drug interaction prediction, and Bayesian therapeutic drug monitoring. Use when analysing concentration-time data, deriving exposure metrics, fitting PK or PD models, or evaluating dosing regimens. Triggers include "pharmacokinetics", "pharmacodynamics", "PK/PD", "NCA", "non-compartmental", "AUC", "Cmax", "lambda z", "half-life", "clearance", "volume of distribution", "compartmental model", "population PK", "popPK", "NONMEM", "nlmixr2", "Pharmpy", "Monolix", "exposure-response", "Emax", "EC50", "indirect response", "effect compartment", "TMDD", "PBPK", "bioequivalence", "RSABE", "ABEL", "allometric scaling", "first-in-human", "MABEL", "drug-drug interaction", "DDI", "ICH M12", "concentration-QTc", "therapeutic drug monitoring", "MIPD", and "dosing regimen".

日本語の概要は準備中です。原文の説明を表示しています。

Use when the user asks to "codify how our founder sounds", "build a founder voice dossier", or "set our content pillars"; runs an 80%-extraction interview over the user's OWN posts, emails, and decks (never competitor scraping, never an invented persona) and produces the versioned voice record — a per-platform register map (incl. 小红书/微信公众号), banned phrases, per-context disclosure lines (the ECHO C2 upstream), a few-shot bank built exclusively from own posts, and 3-5 content pillars with Estimated %-allocations — submitted via memory/events/channels.ndjson for channel-registry to store as voice-dossier.md, the record every Craft-phase skill reads first. Not for the brand-level voice canon — use brand-language-codifier; not for audience/persona research — use audience-mapper. 声音档案/品牌语气/创始人语气/内容支柱/披露声明

日本語の概要は準備中です。原文の説明を表示しています。